Signify Bio, a Dallas, TX-based biotechnology company harnessing the human body for the production of in situ protein therapeutics, raised $15M in initial funding.
The round was led by Actium Group with participation from the Gates Foundation Strategic Investment Fund, Danaher Ventures LLC, a subsidiary of Danaher Corporation, Eli Lilly and Company, and BrightEdge, the American Cancer Society’s (ACS) venture capital arm.
The company intends to use the funds to expand operations and its R&D efforts.
Signify Bio is a biotechnology company improving the development of in situ protein therapeutics by leveraging the human body’s natural ability to produce proteins. Guided by its mission to create personalized medicines for all, it combines the precision of signal peptide engineered control with the speed and versatility of mRNA encoded design. The company’s SEND platform and iPhos lipid nanoparticles enable targeted and localized delivery of therapeutic proteins, addressing unmet needs across various diseases.
The management team includes:
- Daniel J. Siegwart, Ph.D., Co-founder and Chief Scientific Advisor, Director of the Program in Genetic Drug Engineering at UT Southwestern, Professor and W. Ray Wallace Distinguished Chair in Molecular Oncology Research, Departments of Biomedical Engineering and Biochemistry at UT Southwestern, Co-founder of ReCode Therapeutics;
- RA Session II, Co-founder, President, and Chief Executive Officer, former President, CEO, and Founder of Taysha Gene Therapies and former Chief Business Officer of the gene therapy subsidiaries of BridgeBio, former Board Member of ReCode Therapeutics;
- Lukas J. Farbiak, Ph.D., Co-founder and Chief Technology Advisor, Assistant Professor, Departments of Biomedical Engineering and Biochemistry at UT Southwestern;
- David Morrissey, Ph.D., Chief Scientific Officer, former Vice President, Head RNA Accelerator at Pfizer and Senior Vice President, Platform & Delivery Technology at Intellia Therapeutics;
- Morag Stewart, Ph.D., Vice President of Translational Biology, former Senior Director, RNA Medicines at Pfizer Centers for Therapeutic Innovation and Head of Exploratory Biology at Flagship Pioneering.
FinSMEs
05/06/2025